Physicochemical Properties
| Molecular Formula | C108H206N52O24 |
| Molecular Weight | 2617.13 |
| Appearance | White to off-white solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | p53 amyloid formation[1]. |
| ln Vitro | ReACp53 enters primary cancer cells HGSOC and changes mutant p53 from a punctate state to a soluble form that resembles WT p53. ReACp53 also causes p53 degradation, cell cycle arrest, and death of cancer cells. When cultivated as organoids, ReACp53 selectively affects the viability and proliferation of cancer cells expressing mutant p53 but not wild type[1]. |
| ln Vivo | ReACp53 can inhibit tumor growth and reduce tumor size; only mutant p53-bearing tumors in the ReACp53-treated mice cohorts weigh 80–90% less than the control cohort. ReACp53-treated OVCAR3 xenografts show a marked decrease in Ki67 positive cells, which is suggestive of a lower proliferative index. In the minimal residual disease model, comparable outcomes are noted. According to the paradigm, p21 and MDM2 transcription is significantly increased in OVCAR3 xenografts but not in MCF7 xenografts when ReACp53 is administered. Upon ReACp53 injection in vivo, a markedly increased population is also observed in the G0/G1 phase, indicating proliferative arrest[1]. |
| References |
[1]. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 2016 Jan 11;29(1):90-103. |
Solubility Data
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~38.21 mM) H2O :~25 mg/mL (~9.55 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (0.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 50 mg/mL (19.10 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3821 mL | 1.9105 mL | 3.8210 mL | |
| 5 mM | 0.0764 mL | 0.3821 mL | 0.7642 mL | |
| 10 mM | 0.0382 mL | 0.1910 mL | 0.3821 mL |